The staging method developed by Braak and Braak suggests that the neurofibrillary pathology of AD progresses in a relatively predictable sequence across the medial temporal lobe structures, subcortical nuclei, and neocortical areas of the brain in seven stages, with the final stage representing the presence of cortical neurofibrillary changes.
Read more about how Braak’s neurofibrillary pathology correlates with cognitive impairment
Related content
Advances in blood biomarkers are transforming the diagnosis and prognosis of Alzheimer’s disease, helping to assess pathology, disease progression, and co-existing pathologies.
Overview of how blood-based biomarkers may support screening, diagnosis, staging, prognosis, and treatment decisions across the Alzheimer’s disease continuum.
Overview of a plasma biomarker testing pathway for symptomatic Alzheimer’s disease, using p-tau217 and eMTBR-tau243 to guide diagnostic assessment and identify underlying pathology.